| Assessment Status | Awaiting full HTA submission from Applicant |
| HTA ID | 24005 |
| Drug | Fezolinetant |
| Brand | Veoza™ |
| Indication | Fezolinetant is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause. |
| Assessment Process | |
| Rapid review commissioned | 09/02/2024 |
| Rapid review completed | 12/03/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fezolinetant compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 08/04/2024 |
| Pre-submission consultation with Applicant | 24/04/2024 |
